BCAX BICARA THERAPEUTICS INC.

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that company leadership will participate in multiple upcoming investor conferences.

Ryan Cohlhepp, Pharm.D., President and Chief Operating Officer at Bicara will take part in fireside chats at:

  • TD Cowen 46th Annual Health Care Conference



Date and Time: Monday, March 2, 1:10-1:40 p.m. ET in Boston

  • Barclays 28th Annual Global Healthcare Conference



Date and Time: Tuesday, March 10, 11:30-11:55 a.m. ET in Miami

Bicara management will also attend the 2026 Jefferies Biotech on the Beach Summit, taking place March 10-11 in Miami.

Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under . Replays of the webcasts will be archived and available following each event.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit  or follow us on and .

Contacts

Investors

Jenna Cohen

Media

Amanda Lazaro

1AB



EN
23/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BICARA THERAPEUTICS INC.

 PRESS RELEASE

Bicara Therapeutics Announces Closing of Oversubscribed Public Offerin...

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise pric...

 PRESS RELEASE

Bicara Therapeutics Announces Pricing of $150 Million Public Offering ...

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of ...

 PRESS RELEASE

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics Announces Proposed Public Offering of Common Stock BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Bicara intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered in the public offering, at the public offering price, l...

 PRESS RELEASE

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Bicara Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that company leadership will participate in multiple upcoming investor conferences. Ryan Cohlhepp, Pharm.D., President and Chief Operating Officer at Bicara will take part in fireside chats at: TD Cowen 46th Annual Health Care Conference Date and Time: Monday, March 2, 1:10-1:40 p.m. ET in ...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch